Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

E. Joanna Baxter, Linda M. Scott, Peter J. Campbell et al. · The Lancet · 2005 · 3.4K citations

Life Sciences, Genetics, Hematology +14

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

E. Joanna Baxter, Linda M. Scott, Peter J. Campbell et al. · The Lancet · 2005 · 1.1K citations

Life Sciences, Genetics, Hematology +14

Janus kinase 2 regulates Bcr–Abl signaling in chronic myeloid leukemia

Abhishek Samanta, Bastianella Perazzona, Sharmistha Chakraborty et al. · Leukemia · 2010 · 94 citations · Full text

Life Sciences, Oncology, Pharmacology +13

JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia

Alwin Krämer, Andreas Reiter, Jens Kruth et al. · The Lancet Oncology · 2007 · 78 citations

Life Sciences, Genetics, Hematology +14

Clinical presentation and natural history of patients with essential thrombocythemia and the Philadelphia chromosome

Dominik Stoll, Powers Peterson, Robert E. Exten et al. · American Journal of Hematology · 1988 · 73 citations

Medicine, Hematology, Pathology +14